News | February 12, 2008

CAD Increases Diagnostic Accuracy by 44 Percent, Study Shows

February 13, 2008 - A study has found that Medipattern's B-CAD 2, a computer-assisted detection program, increased the diagnostic accuracy up to 44 percent on lesions less than 1 cm in size, according to Medipattern Corp.

B-CAD v2 is only available outside the U.S.

The study was conducted at the PLA301 Hospital in Beijing, China and was based upon 100 confirmed biopsied cases, comparing the diagnostic accuracy of three reading scenarios: a single physician, double reading with two physicians and a single physician reading with B-CAD. The accuracy of the single physician increased with B-CAD in all categories. According to Medipattern, the most striking result showed a 44 percent improvement in diagnostic accuracy for the single reader with B-CAD v2 on lesions less than 1 cm in size.

The physicians were not aware of the pathology outcomes when reading. The cases were separated into three size categories, malignant cancers greater than 2 cm, ranging from 1 to 2 cm and less than 1 cm. The cases were evaluated using the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) Lexicon. Doctors reading without B-CAD used the lexicon to characterize the lesions in the study and assess the diagnosis. B-CAD automatically finds the edge of the lesion and uses this information to characterize the lesion for the physician. B-CAD further consolidates the information into a detailed report documenting whether the lesion is probably benign or probably malignant.

For more information: www.medipattern.com

Related Content

Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
Enlitic Closes Series B Funding for Artificial Intelligence Solutions for Radiologists
News | Artificial Intelligence | April 08, 2019
Radiology artificial intelligence (AI) company Enlitic announced the close of its $15 million Series B financing round...
iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium
News | Computer-Aided Detection Software | April 04, 2019
iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast...
A smart algorithm developed by iCAD

A smart algorithm developed by iCAD outlines and scores a suspicious lesion seen in an image created using digital breast tomography. Displayed is the probability calculated by the algorithm that the outlined area includes a cancerous lesion. Image courtesy of Emily Conant, M.D.

Feature | Artificial Intelligence | April 03, 2019 | Greg Freiherr
  Editor's Note: This article was updated following the SBI symposium.  
Siemens Healthineers Debuts AI-Rad Companion Chest CT
News | Artificial Intelligence | January 25, 2019
Siemens Healthineers presented its first intelligent software assistant for radiology, the AI-Rad Companion Chest CT,...
Telerad Tech Launches MammoAssist AI Software
Technology | Computer-Aided Detection Software | January 25, 2019
Telerad Tech recently announced the launch of MammoAssist, a new artificial intelligence (AI) product to analyze and...
Videos | Artificial Intelligence | December 13, 2018
ITN Editor Dave Fornell and ITN Contributing Editor Greg Freiherr share their insights on the vendors showing...
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...